Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vectus Biosystems Limited ( (AU:VBS) ) just unveiled an update.
Vectus Biosystems has issued 109,000 new fully paid ordinary shares as part of the employment agreement for its newly appointed Chief Executive Officer and Chief Technology Officer, Dr Tara Speranza. The move signals a strengthening of the company’s executive and technology leadership, potentially supporting its long-term development strategy and aligning management incentives with shareholder interests.
The company confirmed that the shares were issued without a prospectus under the Corporations Act’s exemption provisions and that it remains compliant with its financial reporting and continuous disclosure obligations. This administrative step, accompanied by a cleansing notice, ensures the new shares can be traded on-market and underscores Vectus’s adherence to relevant corporate governance and regulatory requirements.
More about Vectus Biosystems Limited
Vectus Biosystems Limited is an Australian biotechnology company listed on the ASX that focuses on developing novel therapeutic solutions for cardiovascular and related chronic diseases. The company operates from Rosebery, New South Wales, and is building its leadership and technical capabilities to advance its research and development programs in this specialised medical field.
Average Trading Volume: 47,019
Technical Sentiment Signal: Sell
Current Market Cap: A$6.14M
For an in-depth examination of VBS stock, go to TipRanks’ Overview page.